Company
Pharmadax, Inc.
Headquarters: New Taipei City, Taiwan
Market Cap
TW$575.1 Million
TWD as of March 1, 2022
US$20.5 Million
Pharmadax, Inc. Categories
Taiwan Healthcare Drug Manufacturers—Specialty & GenericTaiwan Healthcare Taiwan Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Pharmadax Inc. engages in the pharmaceutical research and development business in Taiwan, the Unites States, China, and internationally. It primarily focuses on the development of oral solid controlled-release technology pellets. The company offers Glyburide, Quetiapine Fumarate ER, and Metoprolol Succinate ER tablets, as well as contract development and/or contract manufacturing services for solid orals. It provides its products for a range of therapeutic areas, including schizophrenia, hypertension, diabetes, cold, Parkinson's disease, ADHD, chronic hepatitis, overactive bladder, and muscle relaxant. The company was founded in 2008 and is headquartered in New Taipei City, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Pharmadax, Inc. has the following listings and related stock indices.
Stock: TWSE: 4191 wb_incandescent